APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cellular Tumor Antigen p53

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cellular Tumor Antigen p53 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025196 pages

Choose your research edition.

Industry ResearchCellular Tumor Antigen p53 Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Cellular Tumor Antigen p53 Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Cellular Tumor Antigen p53 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cellular Tumor Antigen p53 Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cellular Tumor Antigen p53 Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Cellular Tumor Antigen p53 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cellular Tumor Antigen p53 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cellular Tumor Antigen p53 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cellular Tumor Antigen p53 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cellular Tumor Antigen p53 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cellular Tumor Antigen p53 include Z53 Therapeutics, LLC, Tara Immuno-Oncology Therapeutics LLC, Stemline Therapeutics, Inc., SK Biopharmaceuticals Co., Ltd., Shenzen SiBiono GeneTech Co., Ltd., Quark Pharmaceuticals, Inc., PCI Biotech Holding ASA, OSE Pharma SA and ORCA Therapeutics B.V., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cellular Tumor Antigen p53 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cellular Tumor Antigen p53 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cellular Tumor Antigen p53 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cellular Tumor Antigen p53 market size, projected growth trends, production technologies, key applications, and end-use industries.

Cellular Tumor Antigen p53 Segment by Company

Z53 Therapeutics, LLC

Tara Immuno-Oncology Therapeutics LLC

Stemline Therapeutics, Inc.

SK Biopharmaceuticals Co., Ltd.

Shenzen SiBiono GeneTech Co., Ltd.

Quark Pharmaceuticals, Inc.

PCI Biotech Holding ASA

OSE Pharma SA

ORCA Therapeutics B.V.

Eleos Inc.

Critical Outcome Technologies Inc.

Cellceutix Corporation

Aprea AB

American Gene Technologies International Inc.

Advaxis, Inc.

Cellular Tumor Antigen p53 Segment by Type

APR-246

ATRN-502

COTI-2

D-12PGJ3

MJ-05

MX-225

Cenersen Sodium

Others

Cellular Tumor Antigen p53 Segment by Application

Prostate Cancer

Brain Cancer

Ovarian Cancer

Others

Cellular Tumor Antigen p53 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cellular Tumor Antigen p53 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cellular Tumor Antigen p53 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cellular Tumor Antigen p53.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cellular Tumor Antigen p53 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cellular Tumor Antigen p53 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cellular Tumor Antigen p53 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cellular Tumor Antigen p53 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cellular Tumor Antigen p53 Industry Trends Table 2. Cellular Tumor Antigen p53 Industry Drivers Table 3. Cellular Tumor Antigen p53 Industry Opportunities and Challenges Table 4. Cellular Tumor Antigen p53 Industry Restraints Table 5. Global Cellular Tumor Antigen p53 Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cellular Tumor Antigen p53 Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cellular Tumor Antigen p53 Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Cellular Tumor Antigen p53 Sales Market Share by Manufacturers Table 9. Global Cellular Tumor Antigen p53 Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cellular Tumor Antigen p53 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cellular Tumor Antigen p53 Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cellular Tumor Antigen p53 Manufacturers, Product Type & Application Table 13. Global Cellular Tumor Antigen p53 Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cellular Tumor Antigen p53 by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of APR-246 Table 17. Major Manufacturers of ATRN-502 Table 18. Major Manufacturers of COTI-2 Table 19. Major Manufacturers of D-12PGJ3 Table 20. Major Manufacturers of MJ-05 Table 21. Major Manufacturers of MX-225 Table 22. Major Manufacturers of Cenersen Sodium Table 23. Major Manufacturers of Others Table 24. Global Cellular Tumor Antigen p53 Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Cellular Tumor Antigen p53 Sales by Type (2021-2026) & (W Units) Table 26. Global Cellular Tumor Antigen p53 Sales by Type (2027-2032) & (W Units) Table 27. Global Cellular Tumor Antigen p53 Sales Market Share by Type (2021-2026) Table 28. Global Cellular Tumor Antigen p53 Sales Market Share by Type (2027-2032) Table 29. Global Cellular Tumor Antigen p53 Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 30. Global Cellular Tumor Antigen p53 Revenue by Type (2021-2026) & (W Units) Table 31. Global Cellular Tumor Antigen p53 Revenue by Type (2027-2032) & (W Units) Table 32. Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2021-2026) Table 33. Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Prostate Cancer Table 35. Major Manufacturers of Brain Cancer Table 36. Major Manufacturers of Ovarian Cancer Table 37. Major Manufacturers of Others Table 38. Global Cellular Tumor Antigen p53 Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Cellular Tumor Antigen p53 Sales by Application (2021-2026) & (W Units) Table 40. Global Cellular Tumor Antigen p53 Sales by Application (2027-2032) & (W Units) Table 41. Global Cellular Tumor Antigen p53 Sales Market Share by Application (2021-2026) Table 42. Global Cellular Tumor Antigen p53 Sales Market Share by Application (2027-2032) Table 43. Global Cellular Tumor Antigen p53 Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 44. Global Cellular Tumor Antigen p53 Revenue by Application (2021-2026) & (W Units) Table 45. Global Cellular Tumor Antigen p53 Revenue by Application (2027-2032) & (W Units) Table 46. Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2021-2026) Table 47. Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2027-2032) Table 48. Global Cellular Tumor Antigen p53 Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 49. Global Cellular Tumor Antigen p53 Sales by Region (2021-2026) & (W Units) Table 50. Global Cellular Tumor Antigen p53 Sales Market Share by Region (2021-2026) Table 51. Global Cellular Tumor Antigen p53 Sales Forecasted by Region (2027-2032) & (W Units) Table 52. Global Cellular Tumor Antigen p53 Sales Forecasted Market Share by Region (2027-2032) Table 53. North America Cellular Tumor Antigen p53 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. North America Cellular Tumor Antigen p53 Sales by Country (2021-2026) & (W Units) Table 55. North America Cellular Tumor Antigen p53 Sales by Country (2027-2032) & (W Units) Table 56. Europe Cellular Tumor Antigen p53 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Europe Cellular Tumor Antigen p53 Sales by Country (2021-2026) & (W Units) Table 58. Europe Cellular Tumor Antigen p53 Sales by Country (2027-2032) & (W Units) Table 59. Asia Pacific Cellular Tumor Antigen p53 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Asia Pacific Cellular Tumor Antigen p53 Sales by Country (2021-2026) & (W Units) Table 61. Asia Pacific Cellular Tumor Antigen p53 Sales by Country (2027-2032) & (W Units) Table 62. South America, Middle East and Africa Cellular Tumor Antigen p53 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 63. South America, Middle East and Africa Cellular Tumor Antigen p53 Sales by Country (2021-2026) & (W Units) Table 64. South America, Middle East and Africa Cellular Tumor Antigen p53 Sales by Country (2027-2032) & (W Units) Table 65. Global Cellular Tumor Antigen p53 Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global Cellular Tumor Antigen p53 Revenue by Region (2021-2026) & (US$ Million) Table 67. Global Cellular Tumor Antigen p53 Revenue by Region (2027-2032) & (US$ Million) Table 68. Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2021-2026) Table 69. Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2027-2032) Table 70. Z53 Therapeutics, LLC Company Information Table 71. Z53 Therapeutics, LLC Business Overview Table 72. Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Product Portfolio Table 74. Z53 Therapeutics, LLC Recent Development Table 75. Tara Immuno-Oncology Therapeutics LLC Company Information Table 76. Tara Immuno-Oncology Therapeutics LLC Business Overview Table 77. Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Product Portfolio Table 79. Tara Immuno-Oncology Therapeutics LLC Recent Development Table 80. Stemline Therapeutics, Inc. Company Information Table 81. Stemline Therapeutics, Inc. Business Overview Table 82. Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Product Portfolio Table 84. Stemline Therapeutics, Inc. Recent Development Table 85. SK Biopharmaceuticals Co., Ltd. Company Information Table 86. SK Biopharmaceuticals Co., Ltd. Business Overview Table 87. SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio Table 89. SK Biopharmaceuticals Co., Ltd. Recent Development Table 90. Shenzen SiBiono GeneTech Co., Ltd. Company Information Table 91. Shenzen SiBiono GeneTech Co., Ltd. Business Overview Table 92. Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio Table 94. Shenzen SiBiono GeneTech Co., Ltd. Recent Development Table 95. Quark Pharmaceuticals, Inc. Company Information Table 96. Quark Pharmaceuticals, Inc. Business Overview Table 97. Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Product Portfolio Table 99. Quark Pharmaceuticals, Inc. Recent Development Table 100. PCI Biotech Holding ASA Company Information Table 101. PCI Biotech Holding ASA Business Overview Table 102. PCI Biotech Holding ASA Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. PCI Biotech Holding ASA Cellular Tumor Antigen p53 Product Portfolio Table 104. PCI Biotech Holding ASA Recent Development Table 105. OSE Pharma SA Company Information Table 106. OSE Pharma SA Business Overview Table 107. OSE Pharma SA Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. OSE Pharma SA Cellular Tumor Antigen p53 Product Portfolio Table 109. OSE Pharma SA Recent Development Table 110. ORCA Therapeutics B.V. Company Information Table 111. ORCA Therapeutics B.V. Business Overview Table 112. ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Product Portfolio Table 114. ORCA Therapeutics B.V. Recent Development Table 115. Eleos Inc. Company Information Table 116. Eleos Inc. Business Overview Table 117. Eleos Inc. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Eleos Inc. Cellular Tumor Antigen p53 Product Portfolio Table 119. Eleos Inc. Recent Development Table 120. Critical Outcome Technologies Inc. Company Information Table 121. Critical Outcome Technologies Inc. Business Overview Table 122. Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Product Portfolio Table 124. Critical Outcome Technologies Inc. Recent Development Table 125. Cellceutix Corporation Company Information Table 126. Cellceutix Corporation Business Overview Table 127. Cellceutix Corporation Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Cellceutix Corporation Cellular Tumor Antigen p53 Product Portfolio Table 129. Cellceutix Corporation Recent Development Table 130. Aprea AB Company Information Table 131. Aprea AB Business Overview Table 132. Aprea AB Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Aprea AB Cellular Tumor Antigen p53 Product Portfolio Table 134. Aprea AB Recent Development Table 135. American Gene Technologies International Inc. Company Information Table 136. American Gene Technologies International Inc. Business Overview Table 137. American Gene Technologies International Inc. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. American Gene Technologies International Inc. Cellular Tumor Antigen p53 Product Portfolio Table 139. American Gene Technologies International Inc. Recent Development Table 140. Advaxis, Inc. Company Information Table 141. Advaxis, Inc. Business Overview Table 142. Advaxis, Inc. Cellular Tumor Antigen p53 Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Advaxis, Inc. Cellular Tumor Antigen p53 Product Portfolio Table 144. Advaxis, Inc. Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. Cellular Tumor Antigen p53 Distributors List Table 148. Cellular Tumor Antigen p53 Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Cellular Tumor Antigen p53 Product Image Figure 2. Global Cellular Tumor Antigen p53 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cellular Tumor Antigen p53 Market Size (2021-2032) & (US$ Million) Figure 4. Global Cellular Tumor Antigen p53 Sales (2021-2032) & (W Units) Figure 5. Global Cellular Tumor Antigen p53 Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cellular Tumor Antigen p53 Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. APR-246 Image Figure 9. ATRN-502 Image Figure 10. COTI-2 Image Figure 11. D-12PGJ3 Image Figure 12. MJ-05 Image Figure 13. MX-225 Image Figure 14. Cenersen Sodium Image Figure 15. Others Image Figure 16. Global Cellular Tumor Antigen p53 Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Cellular Tumor Antigen p53 Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Cellular Tumor Antigen p53 Sales Market Share by Type (2021-2032) Figure 19. Global Cellular Tumor Antigen p53 Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Cellular Tumor Antigen p53 Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2021-2032) Figure 22. Prostate Cancer Image Figure 23. Brain Cancer Image Figure 24. Ovarian Cancer Image Figure 25. Others Image Figure 26. Global Cellular Tumor Antigen p53 Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Cellular Tumor Antigen p53 Sales Market Share 2021 VS 2025 VS 2032 Figure 28. Global Cellular Tumor Antigen p53 Sales Market Share by Application (2021-2032) Figure 29. Global Cellular Tumor Antigen p53 Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 30. Global Cellular Tumor Antigen p53 Revenue Market Share 2021 VS 2025 VS 2032 Figure 31. Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2021-2032) Figure 32. North America Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 33. North America Cellular Tumor Antigen p53 Sales Market Share by Country (2021-2032) Figure 34. U.S. Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Canada Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Mexico Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Europe Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Europe Cellular Tumor Antigen p53 Sales Market Share by Country (2021-2032) Figure 39. Germany Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 40. France Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 41. U.K. Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Italy Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Netherlands Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Asia Pacific Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Asia Pacific Cellular Tumor Antigen p53 Sales Market Share by Country (2021-2032) Figure 46. China Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Japan Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South Korea Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Southeast Asia Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 50. India Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Australia Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South America, Middle East and Africa Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South America, Middle East and Africa Cellular Tumor Antigen p53 Sales Market Share by Country (2021-2032) Figure 54. Brazil Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 55. South Africa Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Saudi Arabia Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Turkey Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Argentina Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 59. UAE Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Egypt Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 61. Chile Cellular Tumor Antigen p53 Sales and Growth Rate (2021-2032) & (W Units) Figure 62. Global Cellular Tumor Antigen p53 Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Global Cellular Tumor Antigen p53 Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 64. North America Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Figure 65. North America Cellular Tumor Antigen p53 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Europe Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Figure 67. Europe Cellular Tumor Antigen p53 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Asia-Pacific Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Figure 69. Asia-Pacific Cellular Tumor Antigen p53 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. South America, Middle East and Africa Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Figure 71. South America, Middle East and Africa Cellular Tumor Antigen p53 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. Cellular Tumor Antigen p53 Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Cellular Tumor Antigen p53 Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • APR-246
  • ATRN-502
  • COTI-2
  • D-12PGJ3
  • MJ-05
  • MX-225
  • Cenersen Sodium
  • Others
Applications
  • Prostate Cancer
  • Brain Cancer
  • Ovarian Cancer
  • Others
Companies covered
  • Z53 Therapeutics, LLC
  • Tara Immuno-Oncology Therapeutics LLC
  • Stemline Therapeutics, Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • Shenzen SiBiono GeneTech Co., Ltd.
  • Quark Pharmaceuticals, Inc.
  • PCI Biotech Holding ASA
  • OSE Pharma SA
  • ORCA Therapeutics B.V.
  • Eleos Inc.
  • Critical Outcome Technologies Inc.
  • Cellceutix Corporation
  • Aprea AB
  • American Gene Technologies International Inc.
  • Advaxis, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cellular Tumor Antigen p53 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cellular Tumor Antigen p53 Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cellular Tumor Antigen p53 Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cellular Tumor Antigen p53 Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cellular Tumor Antigen p53 Market Dynamics
  1. 2.1 Cellular Tumor Antigen p53 Industry Trends
  2. 2.2 Cellular Tumor Antigen p53 Industry Drivers
  3. 2.3 Cellular Tumor Antigen p53 Industry Opportunities and Challenges
  4. 2.4 Cellular Tumor Antigen p53 Industry Restraints
3 Cellular Tumor Antigen p53 Market by Manufacturers
  1. 3.1 Global Cellular Tumor Antigen p53 Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cellular Tumor Antigen p53 Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cellular Tumor Antigen p53 Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cellular Tumor Antigen p53 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cellular Tumor Antigen p53 Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cellular Tumor Antigen p53 Manufacturers, Product Type & Application
  7. 3.7 Global Cellular Tumor Antigen p53 Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cellular Tumor Antigen p53 Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cellular Tumor Antigen p53 Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cellular Tumor Antigen p53 Tier 1, Tier 2, and Tier 3
4 Cellular Tumor Antigen p53 Market by Type
  1. 4.1 Cellular Tumor Antigen p53 Type Introduction
  2. 4.1.1 APR-246
  3. 4.1.2 ATRN-502
  4. 4.1.3 COTI-2
  5. 4.1.4 D-12PGJ3
  6. 4.1.5 MJ-05
  7. 4.1.6 MX-225
  8. 4.1.7 Cenersen Sodium
  9. 4.1.8 Others
  10. 4.2 Global Cellular Tumor Antigen p53 Sales by Type
  11. 4.2.1 Global Cellular Tumor Antigen p53 Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Cellular Tumor Antigen p53 Sales by Type (2021-2032)
  13. 4.2.3 Global Cellular Tumor Antigen p53 Sales Market Share by Type (2021-2032)
  14. 4.3 Global Cellular Tumor Antigen p53 Revenue by Type
  15. 4.3.1 Global Cellular Tumor Antigen p53 Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Cellular Tumor Antigen p53 Revenue by Type (2021-2032)
  17. 4.3.3 Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2021-2032)
5 Cellular Tumor Antigen p53 Market by Application
  1. 5.1 Cellular Tumor Antigen p53 Application Introduction
  2. 5.1.1 Prostate Cancer
  3. 5.1.2 Brain Cancer
  4. 5.1.3 Ovarian Cancer
  5. 5.1.4 Others
  6. 5.2 Global Cellular Tumor Antigen p53 Sales by Application
  7. 5.2.1 Global Cellular Tumor Antigen p53 Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cellular Tumor Antigen p53 Sales by Application (2021-2032)
  9. 5.2.3 Global Cellular Tumor Antigen p53 Sales Market Share by Application (2021-2032)
  10. 5.3 Global Cellular Tumor Antigen p53 Revenue by Application
  11. 5.3.1 Global Cellular Tumor Antigen p53 Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Cellular Tumor Antigen p53 Revenue by Application (2021-2032)
  13. 5.3.3 Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2021-2032)
6 Global Cellular Tumor Antigen p53 Sales by Region
  1. 6.1 Global Cellular Tumor Antigen p53 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cellular Tumor Antigen p53 Sales by Region (2021-2032)
  3. 6.2.1 Global Cellular Tumor Antigen p53 Sales by Region (2021-2026)
  4. 6.2.2 Global Cellular Tumor Antigen p53 Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cellular Tumor Antigen p53 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cellular Tumor Antigen p53 Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cellular Tumor Antigen p53 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cellular Tumor Antigen p53 Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cellular Tumor Antigen p53 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cellular Tumor Antigen p53 Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cellular Tumor Antigen p53 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cellular Tumor Antigen p53 Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cellular Tumor Antigen p53 Revenue by Region
  1. 7.1 Global Cellular Tumor Antigen p53 Revenue by Region
  2. 7.1.1 Global Cellular Tumor Antigen p53 Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cellular Tumor Antigen p53 Revenue by Region (2021-2026)
  4. 7.1.3 Global Cellular Tumor Antigen p53 Revenue by Region (2027-2032)
  5. 7.1.4 Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cellular Tumor Antigen p53 Revenue (2021-2032)
  8. 7.2.2 North America Cellular Tumor Antigen p53 Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cellular Tumor Antigen p53 Revenue (2021-2032)
  11. 7.3.2 Europe Cellular Tumor Antigen p53 Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cellular Tumor Antigen p53 Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cellular Tumor Antigen p53 Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cellular Tumor Antigen p53 Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cellular Tumor Antigen p53 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Z53 Therapeutics, LLC
  2. 8.1.1 Z53 Therapeutics, LLC Company Information
  3. 8.1.2 Z53 Therapeutics, LLC Business Overview
  4. 8.1.3 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Product Portfolio
  6. 8.1.5 Z53 Therapeutics, LLC Recent Developments
  7. 8.2 Tara Immuno-Oncology Therapeutics LLC
  8. 8.2.1 Tara Immuno-Oncology Therapeutics LLC Company Information
  9. 8.2.2 Tara Immuno-Oncology Therapeutics LLC Business Overview
  10. 8.2.3 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Product Portfolio
  12. 8.2.5 Tara Immuno-Oncology Therapeutics LLC Recent Developments
  13. 8.3 Stemline Therapeutics, Inc.
  14. 8.3.1 Stemline Therapeutics, Inc. Company Information
  15. 8.3.2 Stemline Therapeutics, Inc. Business Overview
  16. 8.3.3 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Product Portfolio
  18. 8.3.5 Stemline Therapeutics, Inc. Recent Developments
  19. 8.4 SK Biopharmaceuticals Co., Ltd.
  20. 8.4.1 SK Biopharmaceuticals Co., Ltd. Company Information
  21. 8.4.2 SK Biopharmaceuticals Co., Ltd. Business Overview
  22. 8.4.3 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio
  24. 8.4.5 SK Biopharmaceuticals Co., Ltd. Recent Developments
  25. 8.5 Shenzen SiBiono GeneTech Co., Ltd.
  26. 8.5.1 Shenzen SiBiono GeneTech Co., Ltd. Company Information
  27. 8.5.2 Shenzen SiBiono GeneTech Co., Ltd. Business Overview
  28. 8.5.3 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio
  30. 8.5.5 Shenzen SiBiono GeneTech Co., Ltd. Recent Developments
  31. 8.6 Quark Pharmaceuticals, Inc.
  32. 8.6.1 Quark Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Quark Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Product Portfolio
  36. 8.6.5 Quark Pharmaceuticals, Inc. Recent Developments
  37. 8.7 PCI Biotech Holding ASA
  38. 8.7.1 PCI Biotech Holding ASA Company Information
  39. 8.7.2 PCI Biotech Holding ASA Business Overview
  40. 8.7.3 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Product Portfolio
  42. 8.7.5 PCI Biotech Holding ASA Recent Developments
  43. 8.8 OSE Pharma SA
  44. 8.8.1 OSE Pharma SA Company Information
  45. 8.8.2 OSE Pharma SA Business Overview
  46. 8.8.3 OSE Pharma SA Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OSE Pharma SA Cellular Tumor Antigen p53 Product Portfolio
  48. 8.8.5 OSE Pharma SA Recent Developments
  49. 8.9 ORCA Therapeutics B.V.
  50. 8.9.1 ORCA Therapeutics B.V. Company Information
  51. 8.9.2 ORCA Therapeutics B.V. Business Overview
  52. 8.9.3 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Product Portfolio
  54. 8.9.5 ORCA Therapeutics B.V. Recent Developments
  55. 8.10 Eleos Inc.
  56. 8.10.1 Eleos Inc. Company Information
  57. 8.10.2 Eleos Inc. Business Overview
  58. 8.10.3 Eleos Inc. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eleos Inc. Cellular Tumor Antigen p53 Product Portfolio
  60. 8.10.5 Eleos Inc. Recent Developments
  61. 8.11 Critical Outcome Technologies Inc.
  62. 8.11.1 Critical Outcome Technologies Inc. Company Information
  63. 8.11.2 Critical Outcome Technologies Inc. Business Overview
  64. 8.11.3 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Product Portfolio
  66. 8.11.5 Critical Outcome Technologies Inc. Recent Developments
  67. 8.12 Cellceutix Corporation
  68. 8.12.1 Cellceutix Corporation Company Information
  69. 8.12.2 Cellceutix Corporation Business Overview
  70. 8.12.3 Cellceutix Corporation Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cellceutix Corporation Cellular Tumor Antigen p53 Product Portfolio
  72. 8.12.5 Cellceutix Corporation Recent Developments
  73. 8.13 Aprea AB
  74. 8.13.1 Aprea AB Company Information
  75. 8.13.2 Aprea AB Business Overview
  76. 8.13.3 Aprea AB Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Aprea AB Cellular Tumor Antigen p53 Product Portfolio
  78. 8.13.5 Aprea AB Recent Developments
  79. 8.14 American Gene Technologies International Inc.
  80. 8.14.1 American Gene Technologies International Inc. Company Information
  81. 8.14.2 American Gene Technologies International Inc. Business Overview
  82. 8.14.3 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Product Portfolio
  84. 8.14.5 American Gene Technologies International Inc. Recent Developments
  85. 8.15 Advaxis, Inc.
  86. 8.15.1 Advaxis, Inc. Company Information
  87. 8.15.2 Advaxis, Inc. Business Overview
  88. 8.15.3 Advaxis, Inc. Cellular Tumor Antigen p53 Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Advaxis, Inc. Cellular Tumor Antigen p53 Product Portfolio
  90. 8.15.5 Advaxis, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cellular Tumor Antigen p53 Value Chain Analysis
  2. 9.1.1 Cellular Tumor Antigen p53 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cellular Tumor Antigen p53 Production Mode & Process
  6. 9.2 Cellular Tumor Antigen p53 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cellular Tumor Antigen p53 Distributors
  9. 9.2.3 Cellular Tumor Antigen p53 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst